Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01664637 · ClinicalTrials.gov registry record · Phase 2
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
A Phase 2 study, sponsored by Tranzyme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT01664637 is a Phase 2 study that was terminated before completion, run by Tranzyme. The registered enrollment target is 120 participants.
The verdict
NCT01664637, a Phase 2 study, was terminated before completion, sponsored by Tranzyme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.
Interventions
- DRUG Placebo
- DRUG 10 mg TZP-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01664637
The ClinicalTrials.gov registry entry for NCT01664637 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tranzyme, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01664637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01664637 about?
NCT01664637 is a clinical study titled "Diabetic Gastroparesis Efficacy/Safety Study of TZP-102". The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastrop...
What is the current status of trial NCT01664637?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2012-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01664637?
The interventions under investigation include: Placebo (DRUG), 10 mg TZP-102 (DRUG).
Who is sponsoring clinical trial NCT01664637?
This trial is sponsored by Tranzyme, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.